NCT03062956View on ClinicalTrials.gov

A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Dilated Cardiomyopathy

Interventions

DRUG

MYK-491 or placebo

Oral suspension

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

MyoKardia, Inc.

All Listed Sponsors

lead

MyoKardia, Inc.

INDUSTRY